While the number of prescription fills for GLP-1 receptor agonists has continued to increase, health Insurance coverage for ...
Copycat versions of Eli Lilly’s diabetes drug Mounjaro and obesity drug Zepbound were supposed to go away this week. They’re ...
Every month, roughly 100,000 people buy Zepbound directly from Eli Lilly through its website. "It's about the size of a small city," says David Ricks, Eli Lilly's CEO. That's about 10% of the 1 ...
Eli Lilly is expanding the supply and cutting the costs of its weight-loss drug Zepbound, broadening access to more patients without insurance. (Shelby Knowles/Bloomberg via / Getty Images ...
Eli Lilly, the maker of blockbuster weight loss and diabetes drugs Zepbound and Mounjaro, said it will invest an additional $27 billion to build four new manufacturing plants in the United States ...
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or ...
Eli Lilly (LLY), the maker of the blockbuster weight-loss drug Zepbound, announced Wednesday ... that has helped people with obesity. - Image: UCG / Contributor (Getty Images) A group that ...
Every month, roughly 100,000 people buy Zepbound directly from Eli Lilly through its website. "It's about the size of a small city," says David Ricks, Eli Lilly's CEO. That's about 10% of the 1 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results